Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient

Transplant Infectious Disease

Volumn 19, Issue 4, 2017, Pages

  Kassar, Rawan ^a,b   Chang, Janis ^a,b   Chan, An Wen ^b   Lilly, Leslie B ^c   Al Habeeb, Ayman ^b   Rotstein, Coleman ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

complications; dermatologic complication; immunosuppressive regimens; infection and infectious agents; infectious; leflunomide; minimization withdrawal; trichodysplasia spinulosa; trichodysplasia spinulosa associated polyomavirus; viral

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN; KERATIN; LEFLUNOMIDE; MOMETASONE FUROATE; PRESCRIPTION DRUG; TACROLIMUS; TAZAROTENE; CYCLOSPORINE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE;

ACANTHOSIS; ADULT; ALOPECIA; ARM; ARTICLE; BACK; CASE REPORT; CHRONOPHARMACOLOGY; CLINICAL SKIN REACTION; CORTICOSTEROID THERAPY; DERMIS; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; EVENING DOSAGE; EXOCYTOSIS; FACE; FOREHEAD; GRAFT RECIPIENT; HAND PALM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL REGION; KERATOSIS PILARIS ATROPHICANS FACIEI; LEG; LICHEN (DISEASE); LICHEN SPINULOSUS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOCAL THERAPY; LYMPHOCYTIC INFILTRATION; MALE; MANDIBLE; MORNING DOSAGE; NECK; PAPULE; PHYSICAL EXAMINATION; PRESCRIPTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; PUBIC BONE; PUNCH BIOPSY; RASH; SCALP; SKIN BIOPSY; SKIN EPITHELIUM; SLEEP DISORDER; SYSTEMIC THERAPY; THIGH; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TRICHODYSPLASIA SPINULOSA; TRUNK; ULCERATIVE COLITIS; HAIR DISEASE; HAIR FOLLICLE; PATHOLOGY; POLYOMAVIRUS INFECTION; VIROLOGY;

ADRENAL CORTEX HORMONES; ADULT; CYCLOSPORINE; DIAGNOSIS, DIFFERENTIAL; HAIR DISEASES; HAIR FOLLICLE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LIVER TRANSPLANTATION; MALE; POLYOMAVIRUS INFECTIONS; PRURITUS;

EID: 85019176987     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12702     Document Type: Article

References (27)

1. Izakovic J, Buchner SA, Duggelin M, Guggenheim R, Itin PH. [Hair-like hyperkeratoses in patients with kidney transplants. A new cyclosporin side-effect]. Hautarzt. 1995;46:841-846.
2. Haycox CL, Kim S, Fleckman P, et al. Trichodysplasia spinulosa—A newly described folliculocentric viral infection in an immunocompromised host. J Invest Dermatol. 1999;4:268-271.
3. Kazem S, van der Meijden E, Feltkamp MC. The trichodysplasia spinulosa-associated polyomavirus: Virological background and clinical implications. APMIS. 2013;121:770-782.
4. Ponticelli C, Bencini PL. Nonneoplastic mucocutaneous lesions in organ transplant recipients. Transpl Int. 2011;24:1041-1050.
5. Wyatt AJ, Sachs DL, Shia J, Delgado R, Busam KJ. Virus-associated trichodysplasia spinulosa. Am J Surg Pathol. 2005;29:241-246.
6. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 2010;6:e1001024.
7. Matthews MR, Wang RC, Reddick RL, Saldivar VA, Browning JC. Viral-associated trichodysplasia spinulosa: A case with electron microscopic and molecular detection of the trichodysplasia spinulosa-associated human polyomavirus. J Cutan Pathol. 2011;38:420-431.
8. Fischer MK, Kao GF, Nguyen HP, et al. Specific detection of trichodysplasia spinulosa-associated polyomavirus DNA in skin and renal allograft tissues in a patient with trichodysplasia spinulosa. Arch Dermatol. 2012;148:726-733.
9. Schwieger-Briel A, Balma-Mena A, Ngan B, Dipchand A, Pope E. Trichodysplasia spinulosa—A rare complication in immunosuppressed patients. Pediatr Dermatol. 2010;27:509-513.
10. Wanat KA, Holler PD, Dentchev T, et al. Viral-associated trichodysplasia: Characterization of a novel polyomavirus infection with therapeutic insights. Arch Dermatol. 2012;148:219-223.
11. Osswald SS, Kulick KB, Tomaszewski MM, Sperling LC. Viral-associated trichodysplasia in a patient with lymphoma: A case report and review. J Cutan Pathol. 2007;34:721-725.
12. Sperling LC, Tomaszewski MM, Thomas DA. Viral-associated trichodysplasia in patients who are immunocompromised. J Am Acad Dermatol. 2004;50:318-322.
13. Benoit T, Bacelieri R, Morrell DS, Metcalf J. Viral-associated trichodysplasia of immunosuppression: Report of a pediatric patient with response to oral valganciclovir. Arch Dermatol. 2010;146:871-874.
14. Holzer AM, Hughey LC. Trichodysplasia of immunosuppression treated with oral valganciclovir. J Am Acad Dermatol. 2009;60:169-172.
15. Sanofi-Aventis Inc. Product Monograph, ARAVA, Leflunomide, Mfd. Std., Film-coated Tablets 10, 20, 100 mg. Version 7.0 ed. Laval, QC: Sanofi-Aventis Inc.
16. Ferguson ID, Weiser P, Torok KS. A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. Open Rheumatol J. 2015;9:30-35.
17. Boyd AS. Leflunomide in dermatology. J Am Acad Dermatol. 2012;66:673-679.
18. Baughman RP, Lower EE. Treatment of sarcoidosis. Clin Rev Allergy Immunol. 2015;49:79-92.
19. Henao-Martinez AF, Weinberg A, Waldman WJ, Levi ME. Successful treatment of acyclovir-resistant herpes simplex virus type 2 proctitis with leflunomide in an HIV-infected man. J Clin Virol. 2012;54:276-278.
20. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90:419-426.
21. Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010;84:2150-2156.
22. Bazin C. Leflunomide an immunosuppressive drug for antiviral purpose in treatment for BK virus-associated nephropathy after kidney transplantation. inTech; 2012. http://www.intechopen.com/books/antiviral-drugs-aspects-of-clinical-use-and-recent-advances/leflunomide-an-immunosuppressive-drug-for-antiviral-purpose-in-treatment-for-bk-virus-nephropathy-af. Accessed August 24, 2016.
23. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett. 1993;334:161-164.
24. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol (Orlando). 1999;93:198-208.
25. Blanckaert K, De Vriese AS. Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant. 2006;21:3364-3367.
26. van der Meijden E, Kazem S, Dargel CA, van Vuren N, Hensbergen PJ, Feltkamp MC. Characterization of T antigens, including middle T and alternative T, expressed by the human polyomavirus associated with trichodysplasia spinulosa. J Virol. 2015;89:9427-9439.
27. Wu JH, Simonette RA, Nguyen HP, Rady PL, Tyring SK. Small T-antigen of the TS-associated polyomavirus activates factors implicated in the MAPK pathway. J Eur Acad Dermatol Venereol. 2016;30:1061-1062.